Depression is frequently described as a chemical imbalance, specifically a deficiency of serotonin. This explanation became so dominant in popular culture that it shaped how millions of people understand their own illness and why they take the medications they do.
There is just one problem. It is not quite right.
The serotonin deficiency model of depression is an oversimplification that the scientific community has been revising for decades. Depression is a far more complex neurobiological condition than a simple neurotransmitter shortage, and understanding what is actually happening in the depressed brain is not just an intellectual exercise. It has direct implications for why standard antidepressants fail a significant proportion of patients and why newer treatments like TMS and ketamine work through mechanisms that the serotonin model cannot account for.
This post explains what the current neuroscience of depression actually tells us.
The Serotonin Story: What It Got Right and What It Missed
The serotonin hypothesis of depression emerged in the 1960s from observations that drugs affecting serotonin levels also affected mood. It received enormous commercial reinforcement with the introduction of SSRIs in the 1980s, which were marketed as correcting a serotonin deficiency in the same way that insulin corrects a deficiency in diabetes.
The hypothesis was never as well-established as the marketing suggested. No reliable method exists to directly measure serotonin levels in the living human brain. And studies attempting to induce depression by depleting serotonin in healthy volunteers produced mixed and largely unconvincing results.
A landmark 2022 umbrella review published in Molecular Psychiatry, which synthesized the largest body of evidence on the serotonin hypothesis to date, concluded that the evidence did not support a direct relationship between serotonin levels or activity and depression. This did not mean SSRIs do not work. They do, for many patients. But it raised important questions about why they work, which may have less to do with serotonin directly and more to do with downstream effects on neuroplasticity and brain circuit function.
What the Current Neuroscience Actually Shows
Modern understanding of depression involves multiple interacting systems rather than a single neurotransmitter deficit. Here are the most important ones.
Neuroplasticity Deficits
One of the most robust findings in depression neuroscience is that depression is associated with reduced neuroplasticity, the brain’s capacity to form new neural connections, strengthen existing ones, and adapt to new experiences.
Chronic stress and depression suppress the expression of brain-derived neurotrophic factor, a protein that is essential for the growth and survival of neurons and the formation of new synaptic connections. Lower BDNF levels are consistently found in depressed patients and correlate with symptom severity. Antidepressants of multiple classes, not just SSRIs, increase BDNF expression over time, which may be more relevant to their therapeutic effect than their direct neurotransmitter actions.
This neuroplasticity deficit helps explain a characteristic feature of depression that the serotonin model never adequately addressed: the four to six week delay before antidepressants produce their effects. If depression were simply a serotonin shortage, correcting it should produce rapid improvement. The delay suggests that what matters is not the immediate neurotransmitter effect but the slower process of neural remodeling that follows.
Structural Brain Changes
Neuroimaging studies have consistently found measurable structural changes in the brains of people with depression, particularly those with chronic or recurrent illness.
The hippocampus, critical to memory formation, learning, and emotional regulation, shows reduced volume in depressed patients, with the degree of reduction correlating with the duration and severity of depression. The prefrontal cortex, responsible for executive function, emotional regulation, and rational appraisal, also shows reduced volume and activity. The amygdala, the brain’s threat-detection center, tends to be hyperactive, contributing to heightened emotional reactivity and negativity bias.
These structural changes are not simply consequences of feeling bad. They reflect actual changes in the number, density, and connectivity of neurons, driven by chronic cortisol elevation, neuroinflammation, and reduced BDNF signaling.
The Glutamate System
The glutamate system has emerged as one of the most important new frontiers in depression neuroscience. Glutamate is the brain’s primary excitatory neurotransmitter and plays a central role in neuroplasticity, synaptic strength, and the functioning of the prefrontal cortex and hippocampus.
In depression, glutamate signaling in key brain regions is dysregulated in ways that impair synaptic plasticity and weaken the neural circuits that support mood regulation. This glutamatergic dysregulation is not addressed by SSRIs or SNRIs, which do not directly interact with the glutamate system.
This is precisely why ketamine, which works by blocking NMDA receptors and triggering a rapid glutamate surge, produces antidepressant effects in patients who have not responded to multiple SSRIs. It is not a better serotonin drug. It is a completely different class of intervention targeting a completely different system.
Neuroinflammation
Inflammation has become one of the most active areas of depression research in the last decade. A significant subgroup of depressed patients, estimated at 30 to 40 percent, show elevated levels of inflammatory markers including C-reactive protein and interleukin-6, and their depression is associated with a distinct neurobiological profile that responds differently to treatment than non-inflammatory depression.
Inflammatory cytokines cross the blood-brain barrier and interfere with neurotransmitter synthesis, reduce BDNF expression, activate the HPA axis, and directly impair the function of the prefrontal cortex and hippocampus. In patients with inflammatory depression, standard antidepressants that do not address the inflammatory component often produce poor outcomes, which may explain a significant portion of treatment resistance.
The HPA Axis and Stress Response
The hypothalamic-pituitary-adrenal axis, which governs the body’s cortisol stress response, is dysregulated in a substantial proportion of depressed patients. Chronic HPA axis activation produces chronically elevated cortisol, which suppresses hippocampal neurogenesis, impairs prefrontal cortex function, drives neuroinflammation, and reduces BDNF expression.
This creates a self-sustaining biological loop in which depression produces stress, stress produces cortisol, cortisol damages the brain structures that regulate mood, and the damaged mood regulation capacity produces more depression.
The serotonin deficiency model is an oversimplification that the scientific community has been revising for decades. A landmark 2022 umbrella review in Molecular Psychiatry concluded that evidence does not support a direct relationship between serotonin levels and depression. Depression involves multiple interacting neurobiological systems including neuroplasticity deficits, glutamate dysregulation, neuroinflammation, and HPA axis dysfunction.
Current neuroscience points to several interacting systems including reduced neuroplasticity and BDNF expression, structural changes in the hippocampus and prefrontal cortex, glutamatergic dysregulation, neuroinflammation driven by elevated inflammatory cytokines, and HPA axis dysfunction producing chronic cortisol elevation.
Chronic stress and depression suppress BDNF, which is essential for neuron growth and synaptic connection formation. Chronic cortisol elevation damages the hippocampus and impairs prefrontal cortex function. Neuroinflammation directly impairs the function of mood-regulating brain regions. These changes are measurable on neuroimaging and correlate with symptom severity.
The three most consistently affected brain regions in depression are the hippocampus, which shows reduced volume and impaired function affecting memory and emotional regulation, the prefrontal cortex, which shows reduced activity affecting emotional regulation and rational appraisal, and the amygdala, which becomes hyperactive driving heightened emotional reactivity and negativity bias.
Why This Matters for Treatment
Understanding the neuroscience of depression is not just intellectually interesting. It explains the clinical landscape of treatment response and resistance in ways that have direct practical implications.
Why SSRIs work for some patients and not others. Patients whose depression is primarily serotonergic in nature, or whose neuroplasticity can be adequately restored by SSRI-driven BDNF upregulation, tend to respond to SSRIs. Patients whose depression is primarily driven by glutamatergic dysregulation, neuroinflammation, or severe neuroplasticity deficits may not respond to SSRIs regardless of dose or duration.
Why ketamine works where SSRIs fail. Ketamine’s rapid glutamatergic mechanism restores synaptic plasticity in the prefrontal cortex and hippocampus within hours, through a pathway that bypasses the serotonin system entirely. For patients with glutamatergic depression or severe neuroplasticity deficits, this direct mechanism produces results that serotonergic drugs cannot.
Why TMS works. TMS directly stimulates the prefrontal cortex, the region that shows reduced activity in depression, through focused magnetic pulses. By repeatedly activating these circuits, TMS strengthens neural connectivity in the very networks that depression has weakened. It is addressing the structural and functional deficits of depression at their source.
Why treatment-resistant depression exists. When depression involves neuroinflammation, severe structural changes, genetic variations in neurotransmitter metabolism, or a primarily glutamatergic biological profile, treatments that only address the serotonin system are unlikely to produce adequate relief. Treatment resistance is not a mystery. It is a predictable consequence of applying the wrong mechanism to the wrong biological substrate.
Because depression involves multiple neurobiological systems and SSRIs only address the serotonin system. Patients whose depression is primarily driven by glutamatergic dysregulation, neuroinflammation, or severe neuroplasticity deficits may not respond to SSRIs regardless of dose or duration, because the treatment is not targeting the relevant biological mechanism.
Ketamine works through the glutamate system rather than the serotonin system. Its rapid glutamatergic mechanism restores synaptic plasticity in the prefrontal cortex and hippocampus through a pathway that bypasses serotonin entirely. For patients with glutamatergic depression or severe neuroplasticity deficits, this produces results that serotonergic drugs cannot match.
TMS directly stimulates the prefrontal cortex, the brain region that shows reduced activity and volume in depression, through focused magnetic pulses. By repeatedly activating these circuits, TMS strengthens neural connectivity in the networks that depression has weakened, addressing the structural and functional deficits of depression at their source.
Neuroinflammation refers to elevated levels of inflammatory markers in the brain and body. Approximately 30 to 40 percent of depressed patients show elevated inflammatory markers, and their depression responds differently to treatment than non-inflammatory depression. Inflammatory cytokines impair neurotransmitter synthesis, reduce BDNF, and directly damage mood-regulating brain regions.
| What This Means for You |
|---|
| If you have been told you have a chemical imbalance and the medication for it is not working, the neuroscience of depression suggests a more nuanced question: which of the several neurobiological systems implicated in depression is driving your illness, and which treatment targets that system most directly? At NeuPath Mind Wellness, this is the kind of question our psychiatrists are trained to ask. GeneSight genetic testing can identify pharmacogenomic factors affecting your medication response. TMS targets prefrontal cortex deficits directly. Ketamine addresses the glutamate system. These are not alternative medicine. They are the clinical translation of what the neuroscience of depression actually tells us. We offer all of these services at our three South Florida locations in Delray Beach, Boca Raton, and Boynton Beach. |
| Book a free consultation at NeuPath Mind Wellness today. |
